Tarsus Pharmaceuticals Inc
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
TARS$73.83+4.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(In thousands)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash Flows From Operating Activities: | ||
| Net loss | $(35,731) | $(23,419) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 170 | 104 |
| Amortization of intangible assets | 100 | — |
| Accretion of term loan-related costs | 114 | 81 |
| Stock-based compensation | 5,519 | 3,906 |
| Non-cash lease expense | 132 | 151 |
| Unrealized loss on equity investments | 585 | 65 |
| Net amortization/accretion on marketable securities | (290) | (1,484) |
| Change in fair value of equity warrants issued by licensee | 201 | 17 |
| Unrealized gain from transactions denominated in a foreign currency | — | 16 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (13,264) | (2,500) |
| Inventory | (929) | — |
| Other receivables | (383) | 3,165 |
| Prepaid expenses | 1,065 | 257 |
| Other non-current assets | 106 | 38 |
| Accounts payable and other accrued liabilities | 12,335 | (1,046) |
| Accrued payroll and benefits | (7,287) | (1,313) |
| Other long-term liabilities | (232) | (8) |
| Net cash used in operating activities | (37,789) | (21,970) |
| Cash Flows From Investing Activities: | ||
| Proceeds from maturities of marketable securities | 2,500 | 40,301 |
| Purchases of marketable securities | (104,550) | (28,667) |
| Purchases of property and equipment | (174) | (340) |
| Net cash (used in) provided by investing activities | (102,224) | 11,294 |
| Cash Flows From Financing Activities: | ||
| Proceeds from issuance of common stock, net of paid issuance costs | 98,604 | — |
| Proceeds from issuance of pre-funded warrants, net of paid issuance costs | 9,365 | — |
| Proceeds from exercise of equity awards | 802 | 13 |
| Proceeds from term loan | — | 5,000 |
| Net cash provided by financing activities | 108,771 | 5,013 |
| Net decrease in cash and cash equivalents | (31,242) | (5,663) |
| Cash and cash equivalents — beginning of period | 224,947 | 71,660 |
| Cash and cash equivalents — end of period | $193,705 | $65,997 |
| Supplemental Disclosures Noncash Investing and Financing Activities: | ||
| Operating lease right-of-use asset obtained in exchange for operating lease liability | $384 | $116 |
| Interest expense paid in cash | $868 | $593 |
| Offering costs included within accounts payable and accrued liabilities | $275 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.